RMC-6291

Cat. No.: IBDI-432355

RMC-6291 is an orally active and covalent inhibitor of KRAS G12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRAS G12C(ON) and cyclophilin A (CypA). Thus, RMC-6291 prevents KRAS G12C(ON) from signaling via steric blockade of RAS effector binding. RMC-6291 elicits deep and durable suppression on RAS pathway activity in KRAS G12C tumor models.

Product Details

Target	Ras
Molecular Weight	1012.26
SMILES	C[[email protected]](OC)C(N=CC=C1)=C1C(N2CC)=C(CC(C)(C)COC([[email protected]]3NN(C([[email protected]@H](NC([[email protected]](C(C)C)N(C(C4(F)CCN(C(C#CC(N(C)C)(C)C)=O)CC4)=O)C)=O)C[[email protected]]5CN6CCO5)=O)CCC3)=O)C7=C2C=CC6=C7

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.